Anders Ståhlberg
YOU?
Author Swipe
View article: Detecting <scp> <i>TP53</i> </scp> mutations in paired liquid and tissue biopsies from patients with high‐grade serous ovarian carcinoma
Detecting <span> <i>TP53</i> </span> mutations in paired liquid and tissue biopsies from patients with high‐grade serous ovarian carcinoma Open
High‐grade serous ovarian carcinoma (HGSC) is the most lethal form of ovarian carcinoma, often diagnosed at advanced stages due to non‐specific symptoms and the lack of reliable screening methods. This proof‐of‐concept study aimed to devel…
View article: Ultrasensitive Sequencing ( <scp>SiMSen‐Seq</scp> ) for Environmental DNA Applications
Ultrasensitive Sequencing ( <span>SiMSen‐Seq</span> ) for Environmental DNA Applications Open
The use of Next‐Generation Sequencing (NGS) in environmental DNA (eDNA) research offers increased sensitivity in detecting rare species within vast marine ecosystems. However, conventional NGS methods often fail to accurately capture low‐f…
View article: Identifying Key Questions and Challenges in Microchimerism Biology
Identifying Key Questions and Challenges in Microchimerism Biology Open
Microchimerism research has recently gained renewed attention despite known existence of these rare cells for decades. Fetal and maternal microchimeric‐derived cells may have functional capabilities, and are increasingly associated with bo…
View article: Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile
Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile Open
No liquid biomarkers are available for monitoring rhabdomyosarcoma, and treatment evaluation is limited to imaging examinations. Circulating tumor DNA (ctDNA) is a promising disease marker in various malignancies, but generalized ctDNA ass…
View article: Cellular and molecular characterization of γδ T cells in peripheral blood from patients with metastases from cutaneous and uveal melanoma
Cellular and molecular characterization of γδ T cells in peripheral blood from patients with metastases from cutaneous and uveal melanoma Open
T cells can be divided into two major subtypes based on which chains that make up the T cell receptor (TCR): the conventional αβ T cells and the less common γδ T cells. γδ T cells are attractive targets of cancer immunotherapy due to e.g. …
View article: Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity
Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity Open
Recent advances as well as obstacles for immune-based cancer treatment strategies, highlight the notable impact of patient cancer microenvironments on the immune cells and immune targets. Here, we use patient-derived scaffolds (PDS) genera…
View article: Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Genomic profiles of tumor DNA generated by SNP microarray
View article: Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Sanger sequencing of tumor and germline DNA
View article: Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Sequencing results, all data
View article: Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
SNP array results
View article: Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Supplementary figures 1-4, supplementary tables 1-4, and supplementary case information
View article: Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Levels of oncogenic ALK mutations in tissue samples
View article: Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Sequencing results, ALK hotspot mutation sites
View article: Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Coverage with the NB-ALK sequencing panel
View article: Digital sequencing is improved by using structured unique molecular identifiers
Digital sequencing is improved by using structured unique molecular identifiers Open
Digital sequencing uses unique molecular identifiers (UMIs) to correct for polymerase induced errors and amplification biases. Here, we design 19 different structured UMIs to minimize the capacity of primers to form non-specific PCR produc…
View article: Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma
Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma Open
This study underscores STK25 antagonism as a promising therapeutic strategy for the prevention and treatment of HCC in the context of MASH.
View article: Integration of personalised ultrasensitive <scp>ctDNA</scp> monitoring of patients with metastatic breast cancer to reduce imaging requirements
Integration of personalised ultrasensitive <span>ctDNA</span> monitoring of patients with metastatic breast cancer to reduce imaging requirements Open
Circulating tumour DNA (ctDNA) is an emerging biomarker for monitoring cancers. The personalised disease monitoring in metastatic breast cancer (PDM‐MBC) study is an ongoing study instigated to evaluate ctDNA as a biomarker to individualis…
View article: Mechanistic basis of atypical TERT promoter mutations
Mechanistic basis of atypical TERT promoter mutations Open
Non-coding mutations in the TERT promoter ( TERT p), typically at one of two bases −124 and −146 bp upstream of the start codon, are among the most prevalent driver mutations in human cancer. Several additional recurrent TERT p mutations h…
View article: Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Supplementary figures 1-4, supplementary tables 1-4, and supplementary case information
View article: Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Coverage with the NB-ALK sequencing panel
View article: Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis Open
Sequencing results, ALK hotspot mutation sites